Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia

Next Previous
X
Search
Trial Profile

A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUTO-3 (Primary) ; Cyclophosphamide; Fludarabine; Pembrolizumab
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms AMELIA
  • Sponsors Autolus

    • Most Recent Events

    • 23 Feb 2023 Results (n=52; data cut Feb 28, 2022) assessing safety and efficacy of CD19/22 dual-targeting CAR-T (AUTO3) plus pembrolizumab in relapsed/refractory large B cell lymphoma as inpatient or outpatient therapy, published in the Blood.
    • 01 Oct 2021 Results (n=15; data cut-off 1 June 2020) assessing pre-clinical experiments with AUTO3 together with the safety and efficacy results of this phase 1 clinical trial, published in the Nature Medicine.
    • 13 Jul 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top